PARLIAMENTARY WRITTEN QUESTION
Pharmaceutical Price Regulation Scheme (24 July 2018)

To ask the Secretary of State for Health and Social Care, if he will make it his policy to maintain the current cost-effectiveness threshold per quality-adjusted life year in the next Pharmaceutical Price Regulation Scheme.

Asked by:
Darren Jones (Labour)

The Government is committed to supporting the United Kingdom life sciences industry and ensuring that patients can access cost-effective innovative medicines and technologies at a price the National Health Service can afford. We have been listening to industry feedback and discussing how the medicines market is likely to evolve over the next five years. These discussions have now moved into a more formal phase and are commercially sensitive. The Government will update Parliament if and when agreement is reached.

Answered by:
Steve Brine (Conservative)
5 September 2018